CAR-NK cells: A promising cellular immunotherapy for cancer
© 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies,...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2022
|
| Online Access: | https://hdl.handle.net/1721.1/135407.2 |
| _version_ | 1811075560384757760 |
|---|---|
| author | Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu |
| author_sort | Xie, Guozhu |
| collection | MIT |
| description | © 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer. |
| first_indexed | 2024-09-23T10:08:11Z |
| format | Article |
| id | mit-1721.1/135407.2 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T10:08:11Z |
| publishDate | 2022 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/135407.22024-04-19T19:48:59Z CAR-NK cells: A promising cellular immunotherapy for cancer Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu Koch Institute for Integrative Cancer Research at MIT Massachusetts Institute of Technology. Department of Biology © 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer. 2022-02-07T15:10:31Z 2021-10-27T20:23:21Z 2022-02-07T15:10:31Z 2020-09 2020-08 2021-07-15T15:35:38Z Article http://purl.org/eprint/type/JournalArticle 2352-3964 https://hdl.handle.net/1721.1/135407.2 en http://dx.doi.org/10.1016/j.ebiom.2020.102975 EBioMedicine Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/octet-stream Elsevier BV Elsevier |
| spellingShingle | Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu CAR-NK cells: A promising cellular immunotherapy for cancer |
| title | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_full | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_fullStr | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_full_unstemmed | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_short | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_sort | car nk cells a promising cellular immunotherapy for cancer |
| url | https://hdl.handle.net/1721.1/135407.2 |
| work_keys_str_mv | AT xieguozhu carnkcellsapromisingcellularimmunotherapyforcancer AT donghan carnkcellsapromisingcellularimmunotherapyforcancer AT liangyong carnkcellsapromisingcellularimmunotherapyforcancer AT hamjamesdongjoo carnkcellsapromisingcellularimmunotherapyforcancer AT rizwanromee carnkcellsapromisingcellularimmunotherapyforcancer AT chenjianzhu carnkcellsapromisingcellularimmunotherapyforcancer |